A detailed history of Federated Hermes, Inc. transactions in Allovir, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 15,230 shares of ALVR stock, worth $12,184. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,230
Previous 15,205 0.16%
Holding current value
$12,184
Previous $11,000 9.09%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$0.72 - $0.82 $18 - $20
25 Added 0.16%
15,230 $10,000
Q1 2024

May 14, 2024

BUY
$0.64 - $0.78 $8,473 - $10,327
13,240 Added 673.79%
15,205 $11,000
Q4 2023

Jan 31, 2024

BUY
$0.68 - $2.39 $1,336 - $4,696
1,965 New
1,965 $1,000
Q2 2022

Aug 15, 2022

SELL
$3.26 - $7.06 $414,802 - $898,314
-127,240 Reduced 99.89%
144 $1,000
Q1 2022

May 13, 2022

BUY
$6.75 - $13.52 $859,842 - $1.72 Million
127,384 New
127,384 $860,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $74.5M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.